FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ida Iurisci

Research Profile

Chemicals & Drugs

Concepts & Ideas

Disorders

Physiology

Cell Aggregation

Procedures

Immunoassay

Co-author Network

Publications

TOP 3
Ida Iurisci; tyvin rich; Francis Lévi; Pasquale F Innominato; Nicola Tinari; Luciana Irtelli; Michele De Tursi; Antonino Grassadonia; Stefano Iacobelli
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.
Jacques Beau; Ida Iurisci; T Beau; Francis Lévi
[Dynamic circadian system patients under chimiotherapy].
Ida Iurisci; Elisabeth Filipski; Jens Reinhardt; Stéphane Bach; Athos Gianella-Borradori; Stefano Iacobelli; Laurent Meijer; Francis Lévi
Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ida Iurisci (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Ida Iurisci; tyvin rich; Francis Lévi; Pasquale F Innominato; Nicola Tinari; Luciana Irtelli; Michele De Tursi; Antonino Grassadonia; Stefano Iacobelli
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):e17-9.
2007: Jacques Beau; Ida Iurisci; T Beau; Francis Lévi
[Dynamic circadian system patients under chimiotherapy].
Pathologie-biologie 2007;55(3-4):171-5.
2006: Ida Iurisci; Elisabeth Filipski; Jens Reinhardt; Stéphane Bach; Athos Gianella-Borradori; Stefano Iacobelli; Laurent Meijer; Francis Lévi
Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.
Cancer research 2006;66(22):10720-8.
2006: Gabriel A Rabinovich; Albana Cumashi; German Ariel Bianco; Domenico Ciavardelli; Ida Iurisci; Maurizia D'Egidio; Enza Piccolo; Nicola Tinari; Nikolay E Nifantiev; Stefano Iacobelli
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis.
Glycobiology 2006;16(3):210-20.
2005: Anna Maria Valentini; Palma A Iacovazzi; Mario Correale; Michele Pirrelli; Raffaele Armentano; S Iacobelli; Nicola Tinari; Ida Iurisci; Maria Lucia Caruso
Immunohistochemical and serological 90K/Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2005;1(2):185-9.
2004: Antonino Grassadonia; Nicola Tinari; Ida Iurisci; Enza Piccolo; Albana Cumashi; Pasquale F Innominato; Maurizia D'Egidio; Clara Natoli; Mauro Piantelli; Stefano Iacobelli
90K (Mac-2 BP) and galectins in tumor progression and metastasis.
Glycoconjugate journal 2004;19(7-9):551-6.
2000: Ida Iurisci; Nicola Tinari; Clara Natoli; Domenico Angelucci; Ettore Cianchetti; Stefano Iacobelli
Concentrations of galectin-3 in the sera of normal controls and cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1389-93.